Recurrent Glioblastoma
Oncology·MeSH: Brain Neoplasms
Prevalence
3.2 / 100K
Incidence
3.2 / 100K/yr
9 drugs in development·8 companies·16 clinical trials
Drug Pipeline by Phase
Phase 2(4)
Phase 1(3)
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| [68ga]ga-neob | Novartis AG (NVS) |
Phase 4(1)
| Drug | Company |
|---|---|
| [177lu]lu-neob | Novartis AG (NVS) |
Compare drugs
Frequently asked questions
How many drugs are in development for Recurrent Glioblastoma?
BioSniper tracks 9 drugs in development for Recurrent Glioblastoma across 8 companies.
How many clinical trials target Recurrent Glioblastoma?
There are 16 clinical trials targeting Recurrent Glioblastoma tracked by BioSniper.
What is the prevalence of Recurrent Glioblastoma?
The estimated prevalence of Recurrent Glioblastoma is approximately 3.2 per 100,000 population.
Deep-dive into Recurrent Glioblastoma
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis